Evidence map›Paper›PMID 42070083›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

AAVrh32.33 capsid demonstrates unexpected dermal tropism regardless of immunodominant epitope.

Motahareh Arjomandnejad, Kingsley Essien, Katelyn Sylvia, Meghan Blackwood, Amanda Tutto, Erica Katz, Qiushi Tang, John E Harris, Allison M Keeler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Motahareh ArjomandnejadHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Kingsley EssienDepartment of Medicine, Division of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Katelyn SylviaHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Meghan BlackwoodHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Amanda TuttoHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Erica KatzDepartment of Medicine, Division of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Qiushi TangHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
John E HarrisDepartment of Medicine, Division of Dermatology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA; Department of Dermatology, Mass General Brigham, Boston, MA 02114, USA.
Allison M KeelerHorae Gene Therapy Center, Department of Gene and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA; NeuroNexus Institute, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA. Electronic address: allison.keeler@umassmed.edu.

Funding

Vector Immunology CoreP01HL158506 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Terence R. Flotte · 2021 to 2026
$19.5M
NHLBI NIH HHS P01 HL158506
6 · The paper itself

Abstract

Cutaneous gene therapy has the potential to treat a wide range of skin disorders, but effective delivery remains limited by the barrier properties and immune surveillance of the skin. Here, we identify AAVrh32.33 as a potent vector for targeting dermal stromal compartments. Following systemic administration in mice, AAVrh32.33 mediated robust and durable transgene expression, with preferential targeting of dermal fibroblasts and hair follicle bulge cells. Expression peaked at 1 month and persisted for up to 2 years, highlighting its suitability for chronic conditions. To reduce immunogenicity, a dominant CD8

Indexed as

CapsidCapsid ProteinsDependovirusGenetic VectorsImmunodominant EpitopesViral TropismAnimalsDermisFibroblastsGene Therapy AgentsGenetic TherapyHumansMiceSkinTransduction, GeneticTransgenesCapsid ProteinsImmunodominant EpitopesAAVAAV capsid immunomodulationAAVrh32.33adeno-associated virusdermal trophic AAVdermal tropismfibroblast tropic AAVimmunodominant peptide removed AAVrh32.33skin-directed gene therapyskin trophic AAV

Identifiers

PMID42070083
PMCPMC13261998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.